WHO commits to source drugs and vaccines from 'green' suppliers

By Gareth Macdonald contact

- Last updated on GMT

iStock/Pogonici
iStock/Pogonici

Related tags: World health organization

The WHO has agreed to source drugs from manufacturers which use sustainable production methods.

UN agencies procure more than $3bn (€2.8bn) worth of medicines – generic anti-retroviral drugs, malaria and tuberculosis treatments and vaccines – from manufacturers for their healthcare programmes each year.

This week, the World Health Organization (WHO) joined other UN agencies by agreeing​ to source from producers the use “green” methods. The Geneva, Switzerland-based agency said the move sends an important message to suppliers and manufacturers.

Spokesman Gregory Härtl told us it is “a broad and high-level commitment to the sustainable development principles we all have agreed to espouse in the context of our procurement practices and in the context of our engagement with suppliers.

We would expect that manufacturers would strive to adopt sustainable practices as called for under SDG12​.”

Härtl added that although the WHO has not yet had feedback from industry, “interest in this topic has been communicated to industry suppliers and manufacturers by the WHO and the other signatories, for example at the annual UN Global Supplier meetings​.”

Industry pressure

The commitment is in keeping with other industry-focused WHO policies like the active pharmaceutical ingredient (API) prequalification programme​ which, in part, encourages suppliers to improve standards by promising access to regulated markets.

It also fits with other initiatives. In 2014​, for example, the organization sought to encourage the pharmaceutical industry to invest in the development of treatments for diseases predominantly impacting people in the developing world – including Zika virus.

The same year​, the World Health Assembly - the decision making body of the WHO - called on industry and Governments to control drug prices to make them more accessible to patients.

More recently​, the WHO has been examining the economics of the vaccine market in a bid to find ways of improving access to sustainably produced vaccines in low and middle income countries.

Related news

Related products

show more

Integrated Solutions for Accelerated Time to Market

Integrated Solutions for Accelerated Time to Market

Piramal Pharma Solutions | 08-Jun-2021 | Technical / White Paper

Facing capacity constraints? Lock in your program now! With 14 sites around the world providing diverse services ranging from discovery to drug substance...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

Related suppliers

Follow us

Products

View more

Webinars